All In Biotech

Drug Trial Radar · NCT01257906

Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.025%) Topical Gel to Ziana and Placebo

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, VEHICLE-CONTROLLED, PARALLEL-GROUP STUDY COMPARING CLINDAMYCIN PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL (ACTAVIS MID-ATLANTIC LLC) TO ZIANA® (CLINDAMYCIN PHOSPHATE 1.2% AND TRETINOIN 0.025%) GEL (MEDICIS, THE DERMATOLOGY COMPANY®) AND BOTH ACTIVE TREATMENTS TO CLINDAMYCIN PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL PLACEBO (ACTAVIS MID-ATLANTIC LLC) IN THE TREATMENT OF MILD TO SEVERE ACNE VULGARIS

Last checked: Nov 19, 2026Latest source record: Dec 10, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,225 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,225

Actual

Start

May 2010

Primary completion

Oct 2010

Study completion Oct 2010

Sponsor

Lead sponsor
Actavis Mid-Atlantic LLCIndustry
Sponsor type
Industry
First posted
Dec 10, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ZIANA® (clindamycin phosphate 1.2% and tretinoin 0.025%) gel, marketed by Medicis, The Dermatology Company®, is a safe and effective topical therapy used for the treatment of acne vulgaris. Actavis Mid-Atlantic LLC has developed a generic formulation of clindamycin phosphate (1.2%) and tretinoin (0.025%) topical gel and the current study is designed to evaluate the bioequivalence of this formulation to ZIANA®.

Conditions

  • MILD TO SEVERE ACNE VULGARIS

Interventions

  • CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GELDrug

    Topical Gel applied in the evening for 84 days

  • ZIANA®Drug

    Topical Gel applied in the evening for 84 days

  • Vehicle ControlDrug

    Topical Gel applied in the evening for 84 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Therapeutic EquivalenceTime frame: 12-weeks
  2. SuperiorityTime frame: 12-Weeks
  3. SafetyTime frame: 12-Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lotus Labs Pvt. Ltd

    Bangalore, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.